Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
To investigate effects of long-term testosterone (T) therapy in obese men with T deficiency (TD) and type 2 diabetes mellitus (T2DM), data were collected from two observational, prospective, and cumulative registry studies of 561 men with TD receiving T therapy for up to 6 years. A subgroup of obese hypogonadal men with T2DM was analyzed. Weight, height, waist circumference (WC), fasting blood glucose (FBG), glycated haemoglobin (HbA1c) blood pressure, lipid profile, C-reactive protein (CRP), and liver enzymes were measured. A total of 156 obese, diabetic men with T deficiency, aged 61.17 ± 6.18 years, fulfilled selection criteria. Subsequent to T therapy, WC decreased by 11.56 cm and weight declined by 17.49 kg (15.04%). Fasting glucose declined from 7.06 ± 1.74 to 5.59 ± 0.94 mmol/L (P<0.0001for all).HbA1cdecreased from 8.08 to 6.14%, with a mean change of 1.93%. Systolic and diastolic blood pressure, lipid profiles including total cholesterol: HDL ratio, CRP, and liver enzymes all improved (P<0.0001). Long-term T therapy for up to 6 years resulted in significant and sustained improvements in weight, T2DM, and other cardiometabolic risk factors in obese, diabetic men with TD and this therapy may play an important role in the management of obesity and diabetes (diabesity) in men with T deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“Therapeutic approaches to treatment of obesity and diabetes include bariatric surgery, which were reported to be successful in management of this condition, producing rapid and durable weight loss, reductions in CVD events and overall mortality, and sustained remission of diabetes in most patients [73, 74].”
BackgroundInflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 1×
“Obesity is associated with numerous comorbidities including T2DM, hypertension, stroke, and coronary artery disease [48].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Alternative approaches also include the development of stable glucagon like peptide 1 (GLP-1) receptor agonists, which increase insulin secretion and suppress glucagon secretion and appetite [75].”
BackgroundGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Impact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period
Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E., & Colditz, G. A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1581 · Cited by 1,694
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Gender differences in the regulation of blood pressure
Reckelhoff, J. F. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.1199 · Cited by 1,268
The economic burden of obesity worldwide: a systematic review of the direct costs of obesity
Withrow, D., & Alter, D. A. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00712.x · Cited by 1,083 · cited 1×
“Obesity is a public health threat and its prevalence continues to increase worldwide [44, 47].”
BackgroundGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“[82] investigated the effects of lorcaserin together with diet and exercise and counseling in a large number of obese or overweight adults over a period of 52 weeks.”
BackgroundPulse pressure—a review of mechanisms and clinical relevance
Dart, A. M., & Kingwell, B. A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01108-1 · Cited by 836
Metabolic/bariatric surgery worldwide 2008
Buchwald, H., & Oien, D. M. (2009) · Obesity Surgery · doi:10.1007/s11695-009-0014-5 · Cited by 826 · cited 1×
“Therapeutic approaches to treatment of obesity and diabetes include bariatric surgery, which were reported to be successful in management of this condition, producing rapid and durable weight loss, reductions in CVD events and overall mortality, and sustained remission of diabetes in most patients [73, 74].”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 2×
“A significant association between TD and BMI and WC was noted in 355 male patients with T2DM (mean age 58 years) [27].”
BackgroundResulton behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 18×
“Clearly, it is established that the increased incidence of obesity and T2DM contributes to higher incidence of CVD, hypertension, stroke, cancer, and increased mortality [17, 18].”
BackgroundInfluentialFrequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631 · cited 1×
“The proportion ofmen with TDwas increased inmen with T2DM [79].”
BackgroundRaz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614 · cited 2×
“Also the use of dipeptidyl peptidase inhibitors (DPP-4) to increase the intracellular level of endogenous GLP-1 has been proposed [78].”
BackgroundEffects of weight loss on regional fat distribution and insulin sensitivity in obesity.
Goodpaster, B. H., Kelley, D. E., Wing, R. R., Meier, A., & Thaete, F. L. (1999) · Diabetes · doi:10.2337/diabetes.48.4.839 · Cited by 608
Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990) · Metabolism · doi:10.1016/0026-0495(90)90297-p · Cited by 567
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548 · cited 2×
“[28] examined the effects of T therapy on IR, CVD risk, and symptoms of T deficiency in men with T2DM and/or MetS over a 12-month trial period.”
BackgroundEffect of BMI on Lifetime Risk for Diabetes in the U.S.
Narayan, K. M. V., Boyle, J. P., Thompson, T. J., Gregg, E. W., & Williamson, D. F. (2007) · Diabetes Care · doi:10.2337/dc06-2544 · Cited by 510
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Caminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444
Testosterone and Metabolic Syndrome: A Meta-Analysis Study
Corona, G., Monami, M., Rastrelli, G., Aversa, A., Tishova, Y., Saad, F., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01991.x · Cited by 400 · cited 1×
“[33] showed that T therapy was associated with marked reduction in fasting blood glucose, HOMA-IR, TG, and WC with concomitant increase in high density lipoprotein-cholesterol (HDL), suggesting that T therapy improves metabolic control and may ameliorate central obesity [33].”
BackgroundSelf-citationBoyanov, M. A., Boneva, Z., & Christov, V. G. (2003) · The Aging Male · doi:10.1080/tam.6.1.1.7 · Cited by 381
Waist Circumference and All-Cause Mortality in a Large US Cohort
Jacobs, E. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.201 · Cited by 359
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
Rao, P. M., Kelly, D. M., & Jones, T. H. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.122 · Cited by 292
Relationship of Metabolic Risk Factors and Development of Cardiovascular Disease and Diabetes
Haffner, S. M. (2006) · Obesity · doi:10.1038/oby.2006.291 · Cited by 200
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182 · cited 2×
“[35], in their 18-month study, found the marked decrease in HbA 1c during the last 12 months of their study [35], indicating that these effects may take some time to occur.”
BackgroundHackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168 · cited 2×
“[88] reported a marked reduction in HbA 1c as a result of T therapy, in addition to standard antidiabetic treatment.”
BackgroundSaboor Aftab, S. A., Kumar, S., & Barber, T. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12092 · Cited by 157
Hoyos, C. M., Yee, B. J., Phillips, C. L., Machan, E. A., Grunstein, R. R., & Liu, P. Y. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0525 · Cited by 145
Zitzmann, M., Mattern, A., Hanisch, J., Gooren, L., Jones, H., & Maggi, M. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02853.x · Cited by 122
Diet-Induced Weight Loss Is Associated with an Improvement in β-Cell Function in Older Men
Utzschneider, K. M., Carr, D. B., Barsness, S. M., Kahn, S. E., & Schwartz, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031827 · Cited by 73
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)
Henry, R. R., Chilton, R., & Garvey, W. T. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.011 · Cited by 53 · cited 1×
“Recent studies have provided a critical assessment of the therapeutic options in diabetes and obesity and highlighted the various approaches used to date, including (a) antidiabetics, (b) incretin and glucagon like peptide-1 (GLP1) receptor agonists and dipeptidyl peptidase inhibitors, (c) lifestyle modifications, (d)…”
Method
Cited by
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men
Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S., Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015) · The Aging Male · doi:10.3109/13685538.2015.1004049 · Cited by 312
Dhindsa, S., Ghanim, H., Batra, M., Kuhadiya, N. D., Abuaysheh, S., Sandhu, S., Green, K., Makdissi, A., Hejna, J., Chaudhuri, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1518 · Cited by 286
Corona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0262 · Cited by 217
Self-citationGrossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12664 · Cited by 139
Metadata
- Authors
- Haider, A., Yassin, A., Doros, G., & Saad, F.
- Venue
- International Journal of Endocrinology
- Publisher
- Hindawi Limited
- Published
- 2014
- Volume
- 2014
- Pages
- 1-15
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W1972668697
- Cited by
- 103
- References
- 40
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.